Buy



# **Hindustan Unilever**

Estimate changes
TP change
Rating change

Motilal Oswal values your support in the Asiamoney Brokers Poll 2023 for India Research, Sales, Corporate Access and Trading team. We request your ballot.



Bloomberg	HUVR IN
Equity Shares (m)	2350
M.Cap.(INRb)/(USDb)	6349.4 / 77.4
52-Week Range (INR)	2769 / 2393
1, 6, 12 Rel. Per (%)	-5/-5/-17
12M Avg Val (INR M)	3911

#### Financials & Valuations (INR b)

Y/E March	2023	2024E	2025E
Sales	591.4	643.2	715.7
Sales Gr. (%)	15.5	8.8	11.3
EBITDA	136.3	153.0	173.2
EBITDA mrg. (%)	23.0	23.8	24.2
Adj. PAT	100.2	109.4	124.9
Adj. EPS (INR)	42.7	46.5	53.1
EPS Gr. (%)	13.2	9.1	14.2
BV/Sh.(INR)	213.7	206.3	197.4
Ratios			
RoE (%)	20.3	22.2	26.3
RoCE (%)	26.8	30.1	35.6
Payout (%)	91.4	116.0	116.7
Valuations			
P/E (x)	63.3	58.1	50.9
P/BV (x)	12.6	13.1	13.7
EV/EBITDA (x)	46.2	41.1	36.4
Div. Yield (%)	1.4	2.0	2.3

#### Shareholding pattern (%)

As On	Mar-23	Dec-22	Mar-22
Promoter	61.9	61.9	61.9
DII	11.6	11.6	11.6
FII	14.4	14.3	13.7
Others	12.2	12.2	12.8

FII Includes depository receipts

CMP: INR2,702 TP: INR3,100 (+15% )

Rural demand positive; medium-term outlook promising

- Hindustan Unilever (HUVR)'s 1QFY24 performance fell slightly short of our expectations. During the quarter, volumes grew 3% YoY vs. expectation of 7% growth, as higher inflation is adversely impacting consumer spending.
- In 1QFY24, rural market delivered volume growth. While we expect this momentum to continue; however weather patterns remain a critical factor to monitor.
- The company is normalizing A&P spends to revive volume and bring it back to pre-COVID levels, which represents 9.8% of sales. Management mentioned about funnelling the gross margin expansion towards adspends to drive volume growth. However, the 120bp YoY increase in 'other expenses' is due to a step-up in investments, the impact of new royalty incentives, and favorable benefits in the base quarter.
- The outlook for HUVR remains balanced with lower commodity costs and gradual recovery in rural demand offset by reduced leverage on pricing and increased competition from smaller players in some categories. We reiterate our BUY rating with a TP of INR3,100.

# Performance slightly lower than estimated

- Reported net sales grew 6.1% YoY to INR151.5b (est. INR156.7b). EBITDA grew 8.4% YoY to INR35.2b (est. INR36.6b); PBT grew 9.8% YoY to INR34b (est. INR35.1b); PAT (bei) was up 9.2% YoY to INR25b (est. INR26.5b).
- Underlying volumes grew 3% YoY (est. 7%) during the quarter.
- Segmental performance: Home Care (35% of total sales) revenues were up 10% YoY (four-year CAGR 11.9%), Personal Care (38% of total sales) revenues rose 4.4% YoY (four-year CAGR 5.1%), and Food & Refreshment business sales (25% of total sales) were up 4.7% YoY (four-year CAGR 18.1%).
- **Segmental EBIT**: Home Care margin improved 60bp YoY to 18.3% and Personal Care margin remained flat at 26.3% while Food & Refreshment margin expanded 200bp YoY to 17.9% in 1QFY24.
- Overall **gross margins** for the quarter expanded 260bp YoY and 120bp QoQ to 49.9% (est. 49.6%).
- As a percentage of sales, increase in ad spends (up 50bp YoY to 9.8%), and other expenses (up 150bp YoY to 12.6%) as well as staff costs at 4.3% resulted in EBITDA margin stood at 23.2% (est. 23.4%).

## Management conference call highlights

- HUVR's volume growth for the quarter was 3%, while the FMCG industry volumes grew in mid-single digit. However, on a two-year basis, while its volumes registered a CAGR of 5%, industry volumes were flat.
- Rural recovery appears promising, exhibiting volume growth during the quarter. However, it is crucial to monitor the current weather-related risks.
- Competitive intensity is rising as the share of smaller players increases in certain categories, driven by lower inflation.

Pratik Bipinchandra Prajapati – Research Analyst (pratik.prajapati@motilaloswal.com)

Tanu Jindal - Research Analyst (Tanu.Jindal@MotilalOswal.com)

The YoY rise in 'other expenses' is attributed to a step-up in investments, the impact of new royalty incentives, and favorable benefits in the base quarter

■ The company has experienced a significant impact from commodity cost inflation, resulting in a loss of 600bp. However, there has been a partial recovery of 400bp as of now.

# Valuation and view

- We cut our EPS estimates by ~3-4% for FY24/FY25 to reflect the management commentary on demand, pricing, higher brand investment, and higher tax rates.
- As highlighted in our <u>annual report note</u> earlier in Jun'23, HUVR continues to exhibit remarkable nimbleness, despite its size, led by: 1) its WIMI and clusterbased approach, 2) technological edge over its peers; and 3) strategy of funneling cost savings back into the business for growth.
- Despite its expanded scale, HUVR sustains its dexterity, outperforming peers and maintaining a trajectory of steady growth.
- With improving commentary on rural recovery and commodity cost reductions, we are optimistic that HUVR will return to the mid-to-high teens earnings growth trajectory that it exhibited for four years before the pandemic. We reiterate our BUY rating with a TP of INR3,100.

Quarterly performance (Stan	uaionej											(INR b
Y/E March	-	FY	23			FY	24				FY24	Var.
	1Q	2Q	3Q	4Q	1Q	2QE	3QE	4QE	FY23	FY24E	1QE	vai.
Domestic volume growth (%)	6.0	4.0	5.0	4.0	3.0	5.0	7.0	8.0	5.0	5.8	7.0	
Net sales	142.7	147.5	152.3	148.9	151.5	158.5	165.9	167.4	591.4	643.2	156.7	-3.3%
YoY change (%)	19.8	15.9	16.3	10.6	6.1	7.4	8.9	12.4	15.5	8.8	9.8	
Gross Profit	67.6	67.6	72.3	72.5	75.6	80.6	85.3	85.4	280.0	326.8	77.8	
Margin %	47.4	45.8	47.5	48.7	49.9	50.8	51.4	51.0	47.3	50.8	49.6	
EBITDA	32.5	33.8	35.4	34.7	35.2	37.4	39.8	40.5	136.3	153.0	36.6	-3.9%
YoY change (%)	14.0	7.8	7.9	7.0	8.4	10.9	12.6	16.8	9.0	12.3	12.8	
Margins (%)	22.8	22.9	23.2	23.3	23.2	23.6	24.0	24.2	23.0	23.8	23.4	
Depreciation	2.6	2.5	2.6	2.6	2.6	2.6	2.7	2.9	10.3	10.7	2.8	
Interest	0.3	0.3	0.3	0.2	0.5	0.3	0.3	0.1	1.0	1.1	0.3	
Other income	1.4	1.2	2.3	1.6	1.9	1.4	1.9	1.3	6.4	6.5	1.6	
PBT	31.0	32.2	34.8	33.5	34.0	35.9	38.8	38.9	131.4	147.6	35.1	-3.2%
Tax	8.0	5.8	8.7	8.7	8.9	9.4	10.0	9.9	31.2	38.2	8.6	
Rate (%)	25.7	17.9	25.1	26.1	26.2	26.1	25.8	25.5	23.7	25.9	24.5	
PAT bei	22.9	23.8	25.8	24.7	25.0	26.5	28.8	29.1	100.2	109.4	26.5	-5.8%
YoY change (%)	16.7	8.8	12.6	8.2	9.2	11.5	11.6	17.6	13.2	9.1	15.9	
Extraordinary Inc/(Exp)	-0.1	-0.3	-1.0	0.8	-0.4	0.0	0.0	0.0	-1	-	0.0	
Reported Profit	22 9	26.2	25 1	25.5	24.7	26.5	28.8	29.3	99.6	109 4	26.5	

E: MOFSL Estimates

 $Motilal\ Oswal$ 

**Key Performance Indicators** 

Y/E March		FY23	}			FY2	4	
	1Q	2Q	3Q	4Q	1Q	2QE	3QE	4QE
2Y average growth %								
Volumes	7.5	4.0	3.5	2.0	4.5	4.5	6.0	6.0
Sales	16.3	13.6	13.3	10.8	13.0	11.7	12.6	11.5
EBITDA	10.9	8.5	11.4	8.4	11.2	9.3	10.3	11.9
PAT	10.7	8.1	15.0	8.4	12.9	10.1	12.1	12.9
% sales								
COGS	52.6	54.2	52.5	51.3	50.1	49.2	48.6	49.0
Staff cost	4.2	4.8	4.4	4.6	4.3	5.5	5.4	3.6
Advertising and Promotion	9.3	7.1	7.9	8.7	9.8	10.7	9.9	12.0
Others	11.1	11.1	11.9	12.2	12.6	11.0	12.1	11.1
Depreciation	1.8	1.7	1.7	1.8	1.7	1.7	1.6	1.7
YoY change %								
COGS	27.2	29.8	27.6	12.5	1.0	-2.5	0.8	7.3
Staff cost	-1.0	0.2	-0.6	0.6	0.1	0.7	1.0	-1.0
Advertising and Promotion	0.7	-2.5	-1.2	-0.9	0.5	3.6	2.0	3.4
Others	-1.7	-1.8	-1.0	0.3	1.5	0.0	0.1	-1.0
Other income	104.5	1.8	150.5	31.1	35.0	18.0	-15.0	-17.6
EBIT	14.8	9.1	8.4	7.5	9.3	11.2	13.4	17.4

**Exhibit 1: Segmental performance** 

Exhibit 1: Segmental performance									
Segment Revenue (INR b)	1QFY22	2QFY22	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24
Home Care	38.0	38.4	41.9	47.5	49.3	51.4	55.2	56.4	54.3
Personal Care	45.7	50.0	51.8	47.1	53.6	55.6	57.2	51.9	56.0
Foods & Refreshments	33.2	36.2	34.7	37.0	36.3	37.6	37.0	37.9	38.0
Others	2.3	2.6	2.6	3.0	3.5	2.9	2.9	2.7	3.3
Net Segment Revenue	119.2	127.2	130.9	134.6	142.7	147.5	152.3	148.9	151.5
Growth YoY (%)									
Home Care	11.9	15.7	23.0	23.7	29.9	34.0	31.6	18.7	10.0
Personal Care	13.2	10.3	6.9	3.6	17.3	11.2	10.5	10.1	4.4
Foods & Refreshments	12.2	7.2	3.3	5.3	9.3	3.7	6.8	2.6	4.7
Others	32.2	25.7	0.8	30.2	54.9	10.6	13.2	-9.6	-7.1
Net Segment Revenue	12.8	11.2	10.4	11.0	19.8	15.9	16.3	10.6	6.1
Salience (%)									
Home Care	32	30	32	35	35	35	36	38	36
Personal Care	38	39	40	35	38	38	38	35	37
Foods & Refreshments	28	28	26	27	25	25	24	25	25
Others	2	2	2	2	2	2	2	2	2
Total Segment Revenue	100	100	100	100	100	100	100	100	100
Segment Results (EBIT) - (INR b)									
Home Care	6.6	7.3	8.6	9.4	8.7	8.9	10.6	10.6	9.9
Personal Care	12.9	13.9	14.4	12.4	14.1	14.0	14.4	13.5	14.7
Foods & Refreshments	6.0	6.6	6.5	7.1	5.8	7.4	6.6	6.8	6.8
Others	0.5	0.9	0.7	1.0	1.3	1.0	1.2	1.2	1.2
Total Segment Results	26.0	28.7	30.2	29.8	29.9	31.3	32.8	32.1	32.6
Growth YoY (%)									
Home Care	3.9	7.4	33.7	15.6	31.3	22.1	22.8	12.5	14.0
Personal Care	13.5	4.7	2.0	-1.3	9.6	0.4	-0.3	9.5	4.3
Foods & Refreshments	3.1	18.8	36.6	24.0	-3.7	12.0	2.3	-4.8	17.8
Others	10.2	54.5	46.0	39.1	138.9	17.6	61.6	26.0	-7.0
Total Segment Results	8.4	9.4	17.1	10.2	14.8	9.1	8.4	7.5	9.3
Segmental EBIT margin (%)									
Home Care	17.4	19.0	20.6	19.8	17.6	17.3	19.2	18.7	18.3
Personal Care	28.1	27.8	27.8	26.2	26.3	25.1	25.1	26.1	26.3
Foods & Refreshments	18.1	18.3	18.6	19.3	15.9	19.8	17.9	17.9	17.9
Others	23.9	32.2	28.3	31.8	36.9	34.2	40.4	44.3	36.9
Total	21.8	22.5	23.1	22.2	20.9	21.2	21.5	21.5	21.5
EBIT margin change YoY (bps)									
Home Care	-134	-147	166	-138	19	-168	-138	-104	64
Personal Care	7	-148	-134	-129	-184	-270	-271	-15	-2
Foods & Refreshments	-160	179	454	290	-214	148	-77	-138	200
Others	-476	601	876	205	1,296	205	1,212	1,253	7
Total	-90	-37	133	-16	-92	-132	-158	-62	62

#an inordinately high number; Source: Company, MOFSL



# **Highlights from management commentary**

# **Operational environment**

- HUVR's volume growth for the quarter was 3%, while the FMCG industry volumes grew in mid-single digits. However, on a two-year basis, while HUVR volumes registered a CAGR of 5%, industry volumes were flat.
- The company's volume growth on a two-year CAGR basis is 5% ahead of the market.
- The company is focused on increasing its customer base and sustaining its volume growth.

- Rural recovery appears promising, exhibiting positive volume growth during the quarter. However, it is crucial to monitor the current weather-related risks
- Currently, the business is capturing an impressive 75% market share both in volume and value.
- Price growth would remain flattish or decline if the RM costs continue at their current levels.
- FMCG industry price growth was 22% in the last two years.
- The company expects a gradual recovery in volume, due to the high level of cumulative inflation.
- Competitive intensity rising as the share of smaller players rises in certain categories, driven by lower inflation.

#### **Costs and margins**

- Commodity cost benefit led the gross margin expansion both on a QoQ and YoY hasis.
- A&P spends return to pre-Covid levels to revive volume growth.
- The company has experienced a significant impact from commodity cost inflation, resulting in a loss of 600bp. However, there has been a partial recovery of 400bp as of now.
- The YoY increase in 'Other expenses' is attributed to a step-up in investments, the impact of new royalty incentives, and favorable benefits in the base quarter.
- Consumers are purchasing higher-priced inventory due to the company's destocking strategy.
- Price reduction benefit will be visible in the next two-three quarters.

#### Segmental highlights

## Home care

- Volumes grew in mid-single digits.
- Market development and premiumization led the double-digit growth in both fabric care and household category.

## Beauty and personal care

- BPC grew in mid-single digits
- Strong performance in premium portfolio led to double-digit growth in skin care and color cosmetics.
- The Hair Care segment achieved a mid-single-digit UVG, driven by the strong performance of brands like Tresemme, Indulekha, and Clinic Plus.
- Skin Cleansing had a modest volume-led growth with Lux and Hamam continuing to outperform. Additionally, the company implemented price reductions during the quarter.
- The Oral Care segment delivered strong double-digit growth, led by Closeup.
- The company's new launches included Dove Men+ Care range, Indulekha Soap, and Pond's Anti Pigmentation Serum.

#### **Food & Refreshment**


- The tea segment witnessed modest volume-led growth as consumers continued to downgrade their choices, opting for loose tea over premium teas due to higher inflation in the latter.
- The Health Food Drinks (HFD) category experienced strong growth, driven by the strong performance of both Horlicks and Boost.
- The food segment achieved mid-single digit growth, primarily fueled by the strong performance in Ketchup and Food Solutions categories.
- The Ice Cream segment recorded mid-single digit growth, despite facing exceptionally high base and the impact of unseasonal rains.
- The company's new launches include Horlicks Millet Biscuits, range of Knorr Chinese Sauces, and Bru Cold Coffee.

# Other points

■ In 1QFY24, the effective tax rate stood at 26.5% and is expected to decrease on a full-year basis.


# Story in charts

Exhibit 2: Volume grew 3% YoY




Source: Company, MOFSL

Exhibit 3: On a two-year average basis, underlying volumes rose 4.5% YoY



Source: Company, MOFSL

Exhibit 4: Commodity prices soften on a YoY basis




Source: Company presentation

Exhibit 5: Gross margin expanded 260bp YoY...



Source: Company, MOFSL

Exhibit 6: ...A&P spends increased 50bp YoY to 9.8%...




Source: Company, MOFSL

Exhibit 7: ...employee expenses flat YoY to 4.3%...



Source: Company, MOFSL

Exhibit 8: ...other expenses increased 150bp YoY to 12.6%...



Source: Company, MOFSL

■ EBITDA margin (%) 25.0 25.1 25.0 24.6 24.4 24.1 24.1 23.9 23.3 23.2 23.2 22.9 22.8 1QFY23 2QFY22 4QFY22 2QFY23 1QFY21 2QFY21

Exhibit 9: ...leading to 50bp expansion of EBITDA margin

Source: MOFSL, Company

# Valuation and view

# A strong wealth generator for the last 10 years

- The company's newfound nimbleness in response to raw material costs and competitive stimuli has reinvigorated earnings momentum, achieving strong double-digit growth over this period. Best-of-breed analytics have further boosted growth.
- The strong execution of its Winning in Many Indias (WiMI) strategy has meant that growth in Central India is 1.5x of base growth. Its execution strategies for herbal products and the recent acquisition of GSKCH have been remarkable.
- The focus on premiumization, particularly evident in Detergents and Tea, has meant that even these highly penetrated, large categories have grown significantly. The company's rigorous focus on cost savings has resulted in an unprecedented EBITDA margin improvement over the years.
- Despite being the largest consumer company in India over the past decade ending FY23, HUVR's sales/EBITDA/PAT CAGR stood at a healthy 8.7%/13.0%/12.1%. Given the weak earnings growth posted by its peers in recent years, HUVR's performance has been even more impressive over the last 3/5 years, with an EBITDA CAGR of 12.4%/13.4% and a PAT CAGR of 14.1/13.6%.

### Our investment case for HUVR

- We cut our EPS estimates by ~3-4% for FY24/FY25 to reflect the management commentary on demand, pricing, higher brand investment, and higher tax rates.
- As highlighted in our <u>annual report note</u> earlier in Jun'23, HUVR continues to exhibit remarkable nimbleness, despite its size, led by: 1) its WIMI and clusterbased approach, 2) technological edge over its peers; and 3) strategy of funneling cost savings back into the business for growth.
- Despite its expanded scale, HUVR sustains its dexterity, outperforming peers and maintaining a trajectory of steady growth.
- With improving commentary on rural recovery and commodity cost reductions, we are optimistic that HUVR will return to the mid-to-high teen earnings growth trajectory that it exhibited for four years before the pandemic. We reiterate our BUY rating with a TP of INR3,100.

Exhibit 10: We cut our estimate ~3-4% for FY24/FY25

	New es	timates	Old es	timates	Change		
(INR b)	FY24E	FY25E	FY24E	FY25E	FY24E	FY25E	
Sales	643.2	715.7	651.2	725.9	-1.2%	-1.4%	
EBITDA	153.0	173.2	155.6	177.3	-1.7%	-2.3%	
PAT	109.4	124.9	113.8	128.5	-3.9%	-2.8%	

Source: MOFSL







Exhibit 12: P/E (x) for the Consumer sector



Source: Bloomberg, MOFSL

Source: Bloomberg, MOFSL

# **Financials and valuations**

Income Statement								(INR m)
Y/E March	FY18	FY19	FY20	FY21	FY22	FY23	FY24E	FY25E
Net Sales	3,39,260	3,76,600	3,82,730	4,53,110	5,03,360	5,81,540	6,32,816	7,04,828
Other Oper. Income	5,990	5,640	5,120	6,850	8,570	9,900	10,395	10,915
Total Revenue	3,45,250	3,82,240	3,87,850	4,59,960	5,11,930	5,91,440	6,43,211	7,15,742
Change (%)	8.3	10.7	1.5	18.6	11.3	15.5	8.8	11.3
COGS	1,62,320	1,79,600	1,77,930	2,16,770	2,51,240	3,11,440	3,16,394	3,43,671
Gross Profit	1,82,930	2,02,640	2,09,920	2,43,190	2,60,690	2,80,000	3,26,817	3,72,072
Gross Margin (%)	53.0	53.0	54.1	52.9	50.9	47.3	50.8	52.0
Operating Exp	1,10,170	1,16,270	1,13,920	1,29,950	1,35,660	1,43,680	1,73,796	1,98,836
EBITDA	72,760	86,370	96,000	1,13,240	1,25,030	1,36,320	1,53,021	1,73,236
Change (%)	20.3	18.7	11.1	18.0	10.4	9.0	12.3	13.2
Margin (%)	21.1	22.6	24.8	24.6	24.4	23.0	23.8	24.2
Depreciation	4,780	5,820	9,380	10,690	10,250	10,300	10,738	11,423
Int. and Fin. Charges	200	280	1,060	1,080	980	1,010	1,132	1,188
Other Income - Recurring	5,690	6,640	7,330	5,130	3,930	6,400	6,464	6,984
Profit before Taxes	73,470	86,910	92,890	1,06,600	1,17,730	1,31,410	1,47,614	1,67,608
Change (%)	19.4	18.3	6.9	14.8	10.4	11.6	12.3	13.5
Margin (%)	21.7	23.1	24.3	23.5	23.4	22.6	23.3	23.8
Tax	21,480	27,480	23,940	24,580	27,780	29,220	38,232	42,740
Tax Rate (%)	27.9	30.7	27.4	23.8	24.8	23.7	25.9	25.5
Profit after Taxes	52,990	60,220	67,430	81,240	88,520	1,00,240	1,09,382	1,24,868
Change (%)	24.7	13.6	12.0	20.5	9.0	13.2	9.1	14.2
Margin (%)	15.6	16.0	17.6	17.9	17.6	17.2	17.3	17.7
Reported PAT	52,370	59,780	67,380	78,970	88,180	99,620	1,09,382	1,24,868
Balance Sheet								(INR m)
Y/E March	FY18	FY19	FY20	FY21	FY22	FY23	FY24E	FY25E
Share Capital	2,164	2,165	2,160	2,350	2,350	2,350	2,350	2,350
Reserves	68,590	74,430	78,150	4,71,990	4,85,250	4,99,860	4,82,343	4,61,511
Net Worth	70,754	76,595	80,310	4,74,340	4,87,600	5,02,210	4,84,693	4,63,861
Capital Employed	70,754	76,595	80,310	4,74,340	4,87,600	5,02,210	4,84,693	4,63,861
Gross Block	71,787	59,240	73,400	5,41,570	5,47,640	5,58,290	5,65,290	5,70,291
Less: Accum. Depn.	-30,367	-15,810	-22,840	-31,300	-37,300	-44,240	-54,978	-66,402
Net Fixed Assets incl Goodwill	41,420	43,430	50,560	5,10,270	5,10,340	5,14,050	5,10,312	5,03,889
Capital WIP	4,300	3,730	5,130	6,230	9,010	10,200	10,200	10,200
Investment in Subsidiaries	2,540	2,540	2,500	3,100	6,100	9,810	9,810	9,810
Current Investments	28,570	26,950	12,500	26,850	35,120	28,130	29,130	30,130
Deferred Charges	2,550	3,390	2,610	-59,860	-61,410	-63,250	-63,250	-63,250
Curr. Assets, L&A	92,110	98,615	1,22,720	1,34,710	1,36,800	1,56,060	1,73,574	1,73,346
Inventory	23,590	24,220	26,360	33,830	38,900	40,310	48,678	54,218
Account Receivables	11,470	16,730	10,460	16,480	19,320	27,350	24,272	27,034
Cash and Bank Balance	33,730	36,880	50,170	43,210	36,180	44,220	52,337	39,307
Others	23,320	20,785	35,730	41,190	42,400	44,180	48,286	52,787
Curr. Liab. and Prov.	1,00,736	1,02,060	1,15,710	1,46,960	1,48,360	1,52,790	1,85,083	2,00,265
Account Payables	70,130	70,700	73,990	86,270	88,640	93,910	1,23,116	1,35,106
Other Liabilities	16,376	15,860	25,560	40,270	40,850	41,740	43,827	46,018
Provisions	14,230	15,500	16,160	20,420	18,870	17,140	18,140	19,140
Net Current Assets	-8,626	-3,445	7,010	-12,250	-11,560	3,270	-11,510	-26,918
Application of Funds	70,754	76,595	80,310	4,74,340	4,87,600	5,02,210	4,84,693	4,63,860

E: MOFSL Estimates

 $Motilal\ Oswal$  Hindustan Unilever

# **Financials and valuations**

Ratios								
Y/E March	FY18	FY19	FY20	FY21	FY22	FY23	FY24E	FY25E
Basic (INR)								
EPS	24.5	27.8	31.2	34.6	37.7	42.7	46.5	53.1
Cash EPS	26.7	30.5	35.6	39.1	42.0	47.0	51.1	58.0
BV/Share	32.7	35.4	37.2	201.8	207.5	213.7	206.3	197.4
DPS	20.0	22.0	25.0	40.5	34.0	39.0	54.0	62.0
Payout %	99	96	96	117	90	91	116	117
Valuation (x)								
P/E	110.4	97.1	86.6	78.2	71.7	63.3	58.1	50.9
Cash P/E	101.2	88.6	76.0	69.1	64.3	57.4	52.9	46.6
EV/Sales	17.1	15.4	15.1	13.9	12.5	10.8	9.9	8.9
EV/EBITDA	79.9	67.3	60.2	55.7	50.4	46.2	41.1	36.4
P/BV	82.7	76.4	72.7	13.4	13.0	12.6	13.1	13.7
Dividend Yield (%)	0.7	0.8	0.9	1.5	1.3	1.4	2.0	2.3
Return Ratios (%)								
RoE incl. Goodwill	78.1	81.7	86.0	29.3	18.4	20.3	22.2	26.3
RoCE incl. Goodwill	108.6	118.3	119.8	38.8	24.7	26.8	30.1	35.6
Working Capital Ratios								
Debtor (Days)	12	16	10	13	14	17	14	14
Asset Turnover (x)	4.8	4.9	4.8	1.0	1.0	1.2	1.3	1.5
Leverage Ratio								
Debt/Equity (x)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Cash Flow Statement								(INR b)
Y/E March	FY18	FY19	FY20	FY21	FY22	FY23	FY24E	FY25E
OP/(loss) before Tax	72,850	85,220	90,920	1,04,900	1,17,390	1,30,790	1,47,614	1,67,608
Financial other income	-2,800	-770	-1,630	630	-1,970	-2,430	-6,464	-6,984
Depreciation	4,780	5,240	9,380	10,690	10,400	10,450	10,738	11,423
Net Interest Paid	-2,460	-2,950	-3,940	-2,420	-1,090	-3,240	1,132	1,188
Direct Taxes Paid	-21,880	-26,850	-24,650	-23,670	-27,200	-30,680	-38,232	-42,740
(Incr)/Decr in WC	8,640	-2,610	2,970	-560	-7,890	-8,630	22,897	2,379
CF from Operations	59,130	57,280	73,050	89,570	89,640	96,260	1,37,685	1,32,875
Other Items	4,880	4,460	-8,470	11,910	-1,460	14,050	6,464	6,984
(Incr)/Decr in FA	-8,270	-7,240	-7,020	-39,540	-7,440	-8,610	-7,000	-5,000
Free Cash Flow	50,860	50,040	66,030	50,030	82,200	87,650	1,30,685	1,27,874
(Pur)/Sale of Investments	7,790	3,270	22,490	23,900	-7,930	-4,000	-1,000	-1,000
CF from Invest.	4,400	490	7,000	-3,730	-16,830	1,440	-1,536	984
Dividend Paid	-38,960	-45,460	-62,440	-88,110	-75,190	-84,590	-1,26,900	-1,45,700
Others	-7,550	-9,160	-4,320	-4,690	-4,650	-5,070	-1,132	-1,188
CF from Fin. Activity	-46,510	-54,620	-66,760	-92,800	-79,840	-89,660	-1,28,032	-1,46,888
Incr/Decr of Cash	17,020	3,150	13,290	-6,960	-7,030	8,040	8,117	-13,030
Add: Opening Balance	16,710	33,730	36,880	50,170	43,210	36,180	44,220	52,337
Closing Balance	33,730	36,880	50,170	43,210	36,180	44,220	52,337	39,307

E: MOFSL Estimates

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

# NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL),NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <a href="http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf">http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf</a>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage transactions. Details of pending Enquiry Proc llaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx of Motilal Enquiry Proceedings Oswal Limited Financial Services available are

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

#### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

#### For Hong Kong:

Disclosures

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the 1934 act and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore
In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co. Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore. As per the approved agreement under Paragraph 9 of Third Schedule of Securities and Futures Act (CAP 289) and Paragraph 11 of First Schedule of Financial Advisors Act (CAP 110) provided to MOCMSPL by Monetary Authority of Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Accordingly, if a Singapore person is not or ceases to be such an institutional investor, such Singapore Person must immediately discontinue any use of this Report and inform MOCMSPL.

#### Specific Disclosures

- MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company
- MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months
- MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- Research Analyst has not served as director/officer/employee in the subject company MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months 6
- MOFSL has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months 8
- MOFSL has not received any compensation or other benefits from third party in connection with the research report
- MOFSL has not engaged in market making activity for the subject company

### The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

13 21 July 2023

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, it does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

#### Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

#### Disclaimer

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No::022-40548085.

Grievance Redressal Cell:

Officialist (Caressar Octi.		
Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Aiay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN .: 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products. Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.